Ownership and insider activity for ADMA Biologics, Inc. (ADMA): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Price
| Price | $11.41 (closing price, October 30, 2026) |
| Market Cap | $2.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-24 | Kestenberg-Messina Kaitlin M. | F-InKind | 3,177 | $27K |
| 2026-07-16 | Kohler Terry | A-Award | 85,130 | |
| 2026-07-16 | Kohler Terry | A-Award | 136,363 | $1.2M |
| 2026-05-27 | Grossman Jerrold B | P-Purchase | 6,400 | $51K |
| 2026-05-12 | Grossman Jerrold B | P-Purchase | 12,500 | $100K |
| 2026-05-11 | Grossman Jerrold B | P-Purchase | 12,500 | $100K |
| 2026-04-01 | Kestenberg-Messina Kaitlin M. | F-InKind | 20,362 | $185K |
| 2026-03-13 | Guiheen Lawrence P. | M-Exempt | 30,000 | $110K |
| 2026-03-17 | Guiheen Lawrence P. | G-Gift | 30,000 | |
| 2026-03-17 | Guiheen Lawrence P. | G-Gift | 30,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.9M | $43.1M | $22.8M | $26.8M | $55.9M | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Short-term Investments | $5.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.0M | $3.9M | $1.4M | $3.5M | $13.2M | $28.6M | $15.5M | $27.4M | $50.0M | $158.4M |
| Inventory | $5.0M | $12.6M | $18.6M | $53.1M | $81.5M | $124.7M | $163.3M | $172.9M | $170.2M | $206.5M |
| Total Current Assets | $21.7M | $63.2M | $44.5M | $85.8M | $153.7M | $208.7M | $270.4M | $257.0M | $331.4M | $466.5M |
| Property, Plant & Equipment | $2.0M | $30.5M | $30.1M | $33.0M | $45.9M | $58.2M | $68.7M | $63.5M | $63.3M | $71.7M |
| Goodwill | 0 | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Intangible Assets | 0 | $4.8M | $4.0M | $3.2M | $2.4M | $1.7M | $1.0M | $499,000 | $460,000 | $632,000 |
| Total Assets | $23.7M | $108.0M | $88.9M | $127.1M | $207.7M | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M |
| Accounts Payable | $2.6M | $5.9M | $5.9M | $9.2M | $11.1M | $12.4M | $13.2M | $15.7M | $20.2M | $22.5M |
| Short-term Debt | $6.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.8M |
| Total Current Liabilities | $11.2M | $9.4M | $9.6M | $14.0M | $19.9M | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M |
| Long-term Debt | $14.1M | $43.0M | $44.1M | $83.2M | $93.0M | $94.9M | $142.8M | $130.6M | $72.3M | $69.3M |
| Total Liabilities | $28.1M | $67.7M | $69.1M | $100.9M | $119.4M | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M |
| Retained Earnings | -$106.9M | -$150.7M | -$216.4M | -$264.7M | -$340.5M | -$412.1M | -$478.0M | -$506.3M | -$308.6M | -$161.7M |
| Total Equity | -$4.5M | $40.3M | $19.8M | $26.2M | $88.2M | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
| Total Debt | $20.3M | $43.0M | $44.2M | $84.7M | $97.7M | $102.9M | $154.4M | $141.4M | $82.1M | $79.9M |
| Net Debt | $5.0M | -$136,720 | $21.5M | $58.0M | $41.7M | $51.8M | $67.9M | $90.1M | -$21.0M | -$7.7M |
| Working Capital | $10.4M | $53.7M | $34.9M | $71.8M | $133.8M | $178.4M | $231.1M | $207.2M | $275.9M | $397.0M |
Financial Health
| Debt / Equity | 0.50 |
| Current Ratio | 6.97 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 19.98 |
Profitability
| Return on Equity | 39.59% |
| Return on Invested Capital | 27.55% |
| Return on Assets | 24.69% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Related companies: GRFS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks